Physicians' Academy for Cardiovascular Education

Covid-19

Overview of recent news and publications on COVID-19 and cardiovascular disease

Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk

3' education - Jan. 11, 2022 - Prof. Freek Verheugt, MD, PhD

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD

No decrease in thrombotic complications in second COVID-19 wave

5' education - Feb. 4, 2021 - Fleur Kaptein, MD

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

Advantages of the digital 2020 ESC Congress

3' education - Sep. 1, 2020 - Prof. Barbara Casadei, MD

Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated

3' education - Aug. 30, 2020 - Prof. Barbara Casadei, MD

Cardiac abnormalities in recovered COVID-19 patients

3' education - July 29, 2020 - Prof. Rudolf de Boer, MD, PhD

Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy

3' education - May 8, 2020 - Enrico Baldi, MD

Venous thromboembolism in COVID-19 patients

5' education - May 6, 2020 - Prof. Saskia Middeldorp

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

COVID-19 associated thrombotic complications

5' education - Apr. 22, 2020 - Erik Klok, MD, PhD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

CAPACITY COVID: a registry of CV variables in patients with COVID-19

3' education - Mar. 31, 2020 - Prof. Folkert Asselbergs, MD, PhD

2022 ACC expert consensus pathway on cardiovascular consequences of COVID-19

News - Mar. 24, 2022

The expert consensus pathway provides recommendations for the evaluation and management of adults with myocarditis and long COVID following COVID-19 infection.

Increased risk of incident CV outcomes in the post-acute phase of COVID-19

Literature - Feb. 15, 2022 - Xie Y et al. - Nat Med. 2022

A study shows that individuals in the post-acute phase of COVID-19 exhibited increased risks and 12-month burdens of incident CV diseases, compared to individuals with no evidence of SARA-CoV-2 infection.

Subclinical multi-organ affection after recovery from mild to moderate COVID-19

Literature - Jan. 20, 2022 - Petersen EL, et al. - Eur Heart J 2021
A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk

3' education - Jan. 11, 2022 - Prof. Freek Verheugt, MD, PhD
Anticoagulation after discharge may be necessary for a short time in patients who were hospitalized due to COVID-19 and have a  high thrombotic risk, according to prof. Verheugt.

Anticoagulation after discharge may be necessary for a short time in patients who were hospitalized due to COVID-19 and have a high thrombotic risk, according to prof. Verheugt.

Extended thromboprophylaxis with NOAC after hospitalization for COVID-19 improves outcomes

Literature - Jan. 11, 2022 - Ramacciotti E, et al. - Lancet 2022

The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the NOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.

Guidance document on diagnosis and management of CVD during the COVID-19 pandemic

News - Dec. 6, 2021

The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.

No change in organ support-free days with P2Y12i in non-critically ill COVID-19 patients

News - Nov. 17, 2021

AHA 2021 As part of the ACTIV-4a study, it was examined whether use of P2Y12 inhibitors (ticagrelor or clopidogrel) changed the number of organ support-free days in a period of 28 days in non-critically ill hospitalized patients with COVID-19.

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD
Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19. patiënten met COVID-19.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

Highly-purified EPA does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD
Is a therapeutic dose of heparin in COVID-19 patients more effective than the standard dose heparin? Prof. ten Cate gives an update on the most recent findings.

Is a therapeutic dose of heparin in COVID-19 patients more effective than standard dose heparin? Prof. ten Cate gives an update on the most recent findings.

Therapeutic-dose of heparin does not improve outcomes in critically ill COVID-19 patients

Literature - Aug. 16, 2021 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, et al. - NEJM 2021
In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

Atypical PF4-dependent thrombosis and thrombocytopenia in some after COVID-19 vaccination

Literature - Apr. 22, 2021 - Scully M, et al. - N Engl J Med. 2021

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

Covid-19